Latest News

Dear Doctor, Aspen Pharmacare Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA), is conducting a retail level recall of Zantac (ranitidine) tablets, effervescent tablets, syrup and ampoules. The TGA has not requested that a Dear Doctor letter be sent for this retail level product recall. We are informing you as the potentially…

Aspen Pharma is lifting the current retail level quarantine and undertaking a product defect correction for one batch Endone tablets -Batch CW612. We are contacting you as our records indicate that units from this particular batch may have been supplied to your organisation. Download Letter Download Letter – TGA

The bottle cap on Span K (potassium chloride) 600mg tablets is not child resistant. Apsen Pharmacare is conducting a recall for product correction to replace the current plain white cap with an enclosed child resistant cap. Future stock will include a child resistant cap.

As of 1 September 2015 Aspen has divested to Strides (Australia) Pharma Pty Ltd a portfolio of its products commercialised in Australia and New Zealand. The range primarily includes the Aspen Generics Product Portfolio and business, including the Chemists’ Own range. Strides, to be called Arrow Pharmaceuticals in Australia, has a core focus on generic product development, and with its strong manufacturing and procurement capabilities has better opportunities to promote and grow this portfolio.

It is with great pleasure and pride we communicate that at the 2014 Aspen Global Recognition Awards held in Johannesburg South Africa on Friday 7 November, John Sedgedin was announced the winner of the Aspen Values Award.

Aspen Nutritionals Australia Pty Ltd is very concerned that a customer has reported finding a lizard in a tin of S-26 Original Progress formula, and is voluntarily withdrawing the affected batch number 40727482A2 while it investigates the issue. No other products or batches are affected, and consumers can continue to use these with confidence.

Aspen Australia is pleased to advise that from the 1st June, 2014 Ferinject® (ferric carboxymaltose) 10ml (500mg) is available on the Pharmaceutical Benefits Scheme (PBS) as a drug for iron deficiency anaemia.# Ferinject® (ferric carboxymaltose) is available in Australia for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests.

Port Elizabeth – The Nelson Mandela Metropolitan University (NMMU) today conferred the degree of Doctor of Commerce (honoris causa) on Stephen Saad, Aspen Group Co-Founder and Chief Executive. Chancellor of the NMMU, Santie Botha said, ‘’It is an honour for NMMU to confer this honorary degree on Stephen Saad. His vision and drive in the world of business is inspiring and as NMMU we acknowledge the turn-around he orchestrated in a Port Elizabeth-based company that provides jobs to people in an economically struggling province’’.